GLP Watchdog

Semaglutide for Menopause Weight Gain: 2026 Sellers: Ranked and Reviewed

Weight gained through perimenopause and menopause resists diet and exercise, and effort is not the variable: estrogen falls, fat moves toward the abdomen, and muscle declines with age. Semaglutide does help (STEP-1 averaged around 15% body-weight loss), and some women take it alongside hormone replacement therapy. Two things deserve more attention at this stage of life than at any other. Protecting muscle and bone through rapid loss, and keeping a GLP-1 and HRT under one prescriber instead of two who each see half.

Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more

By Ruth Calder · Enforcement Editor
Editorially reviewed. Not medical advice · How we verify contentLast reviewed

619 semaglutide providers compared · independently scored against our six-factor methodology.

Price and states served both move. Read them off the seller's own site before you enroll.How our reviews work →

Methodology & sources

Each provider here carries a score from our published six-factor rubric[1], and the list is then cut down to the criteria named in the page title.

Published Phase 3 efficacy for semaglutide 2.4 mg (~14.9% mean weight loss over 68 weeks) comes from the STEP 1 trial[2]. The SURMOUNT-5 head-to-head published in 2025 directly compared tirzepatide and semaglutide[3].

Quick Picks

Starting price per provider. Prices in USD per month; checked November 2026.
#ProviderScore
1EmbodyVisit
2SnagRxVisit
3CollectiveVisit
4CoreAge RxVisit
5LttlVisit

What is known after menopause

Almost none of the evidence was gathered in menopausal women, and the figures below say where each one comes from.

  • 1 review

    specific to peri- and postmenopausal women

    The only review written about this group, in Current Opinion in Obstetrics and Gynecology in 2025, calls GLP-1 drugs consistently the most effective drug class for weight loss and a valuable tool here. It also opens on how little data there is, so anything said about menopause in particular is borrowed from other populations.[4]

    What the menopause literature says →

  • 25% to 35%

    of weight lost that was lean mass

    A 2026 pooled analysis of 20 randomized trials in 15,782 people put lean mass at 25% to 35% of the weight lost, depending on the drug, and at 26% for intensive lifestyle programs. The proportion matches dieting. What differs after menopause is the smaller reserve of muscle it comes out of.[5]

  • RR 0.80

    fracture risk, 25 studies, type 2 diabetes only

    A 2025 meta-analysis of 25 studies found no rise in fracture risk (relative risk 0.80, 95% CI 0.47 to 1.36) and better lumbar spine bone density. Every one of those studies was in type 2 diabetes. Bone loss driven by falling estrogen is a different process, so a history of osteopenia or a fragility fracture belongs in the first appointment.[6]

    Bone density and fracture risk →

  • -1% vs -0.6%

    hip bone density over 17 months, people without diabetes

    A 2026 study matched 255 people on semaglutide or tirzepatide with 255 non-users, a group that was 92% women with a mean age of 64. Hip bone density fell by a similar amount in both arms overall. In those without diabetes it fell 1% on the drugs against 0.6% off them (P = .04), and the loss tracked weight loss. It is one retrospective chart review and the gap is small.[7]

  • Not studied

    a GLP-1 together with hormone therapy

    We found no trial of a GLP-1 taken alongside hormone therapy, and none that measured hot flashes, sleep or other menopausal symptoms. That is an absence of evidence, not a finding of harm.

Detailed Reviews

1

Embody

Verified partner

Best for: a flat compounded tirzepatide or semaglutide price at every dose, from a seller that names its pharmacies

9.3

Embody is the brand Modern Metabolic Medicine, Inc. runs through its JoinEm storefront. It sells compounded semaglutide and tirzepatide injections at one price per drug at every dose, $79 and $129 for a one-month supply, plus a compounded oral tirzepatide gum. You pay at checkout, before an OpenLoop Health clinician decides on a prescription, and payments are final.

Score Breakdown

Value25%
10
Effectiveness25%
10
User Experience15%
8
Trust & Safety15%
9
Accessibility10%
10
Support10%
7
Starting from $79/moRead full review →
Visit Embody →
2

SnagRx

Verified partner

Best for: semaglutide at $99/month, well below the typical price

9.2

SnagRx sells compounded semaglutide at $99 a month and compounded tirzepatide at $149 a month on its 1-month plan, one price at every dose. Longer plans cut the monthly rate but are charged in full up front and are non-refundable. Clinicians come from the OpenLoop Health network; the platform is Modern Metabolic Medicine, Inc. The visit and 1-2 day shipping are included, with no insurance and no membership.

Score Breakdown

Value25%
10
Effectiveness25%
10
User Experience15%
8
Trust & Safety15%
9
Accessibility10%
9.8
Support10%
7
Starting from $99/moRead full review →
Visit SnagRx →
3

Collective

Verified partner

Best for: flat any-dose pricing, if you can absorb a $199 annual membership on top

9.1

Health For Everyone Inc., trading as CollectiveOS, sells compounded semaglutide at $59/mo and compounded tirzepatide at $69/mo on a membership model, with a mandatory $199 annual membership on top that the headline price does not include. It prices every dose the same, so the cost does not climb as the dose is titrated, and it does not require prepaying for medication. The site is marketed as being from the founder of Thrive Market. Neither its pharmacies nor its medical groups are named.

Score Breakdown

Value25%
10
Effectiveness25%
10
User Experience15%
8
Trust & Safety15%
9
Accessibility10%
9
Support10%
7
Starting from $59/moRead full review →
Visit Collective →
4

CoreAge Rx

Verified partner

Best for: flat-priced compounded semaglutide at $79 a month, any dose

9.0

CoreAge Rx charges the same amount at every dose of its compounded GLP-1s: semaglutide is $79 a month, tirzepatide $129. Consult and shipping are inside that figure, and there is no membership fee. You pay before a doctor reviews the case, and every prescription sale is final once it reaches the pharmacy.

Score Breakdown

Value25%
10
Effectiveness25%
10
User Experience15%
8
Trust & Safety15%
7.5
Accessibility10%
9.7
Support10%
7
Starting from $79/moRead full review →
Visit CoreAge Rx →
5

Lttl

Verified partner

Best for: starting below a standard dose, with microdose tiers

9.0

Lttl sells compounded semaglutide at $99 a month and tirzepatide at $149 a month on its month-to-month plan, one flat price at any dose. Prepaying for 12 months lowers those to $89 and $139. Every price and commitment length is on a public plans page before checkout. A microdose line at $149 a month and longevity peptides fill out the catalog.

Score Breakdown

Value25%
10
Effectiveness25%
10
User Experience15%
8
Trust & Safety15%
7.5
Accessibility10%
10
Support10%
7
Starting from $99/moRead full review →
Visit Lttl →
6

YourEra

Verified partner

Best for: semaglutide at $99/month, well below the typical price

9.0

YourEra sells compounded semaglutide and compounded tirzepatide injections through an online visit with a licensed clinician, at one price for every dose. It is run by Your Era Management, L.L.C. in Louisiana, and it names its medical group and its three pharmacies. Semaglutide is $99 a month month-to-month. Tirzepatide is published only as a 12-month prepaid plan averaging $99 a month.

Score Breakdown

Value25%
10
Effectiveness25%
10
User Experience15%
8
Trust & Safety15%
7.5
Accessibility10%
10
Support10%
7
Starting from $99/moRead full review →
Visit YourEra →
7

altRX

Verified partner

Best for: compounded semaglutide from $89/month at the same price at every dose

8.8

Compounded plans open at $89 for semaglutide and $149 for tirzepatide, the same at every dose. Branded medication runs $1,149-$1,579, a figure that already contains the consult and the shipping. Every one of the four FDA-approved brands is stocked, Mounjaro, Ozempic, Wegovy and Zepbound, which no other entry in our directory matches. altRX works in both modalities, holds LegitScript certification, and prints the FDA compounded-medication disclaimer. FDA sent its operator a warning letter in June 2026.

Score Breakdown

Value25%
10
Effectiveness25%
10
User Experience15%
8
Trust & Safety15%
6
Accessibility10%
10
Support10%
7
Starting from $89/moRead full review →
Visit altRX →
8

Eden

Verified partner

Best for: coverage in all 50 states, which most sellers will not confirm

8.7

Eden sells compounded semaglutide and tirzepatide through its own pharmacy network and a contracted provider group. Its price pages promise the same charge at every dose and say there is no membership fee. Its own terms still describe a $39-then-$99 monthly membership with medication billed on top. Semaglutide is $99 a month and tirzepatide $129.

Score Breakdown

Value25%
10
Effectiveness25%
10
User Experience15%
8
Trust & Safety15%
4.5
Accessibility10%
10
Support10%
8.5
Starting from $99/moRead full review →
Visit Eden →
9

Strut Health

Verified partner

Best for: semaglutide at $99/month, well below the typical price

8.6

Strut Health sells LegitScript and ACHC-accredited compounded semaglutide and tirzepatide in injectable and oral lozenge formats, shipping to 49 states. Board-certified US physicians handle prescribing and follow-up messaging is unlimited and free. Eligibility is gated behind a clinician determination of medical necessity that the company does not publicly define.

Score Breakdown

Value25%
10
Effectiveness25%
10
User Experience15%
8
Trust & Safety15%
4.5
Accessibility10%
9.8
Support10%
7
Starting from $99/moRead full review →
Visit Strut Health →
10

Gala

Verified partner

Best for: moving between compounded and brand without changing seller

8.5

A yearly plan is the format: compounded semaglutide and compounded tirzepatide are sold that way, with brand-name Ozempic on the same menu. The corporate name is AI Coaching Inc., which does business as Gala GLP-1 and is incorporated in Delaware; care comes through OpenLoop-affiliated medical groups. Compounded GLP-1 is $179 a month on the yearly plan, all doses included. A Wegovy pill taken orally is flagged as coming soon.

Score Breakdown

Value25%
7.9
Effectiveness25%
10
User Experience15%
8
Trust & Safety15%
7.5
Accessibility10%
10
Support10%
7
Starting from $179/moRead full review →
Visit Gala →

Ranked 11 to 30

The same ranking continues in short form: each seller's score, the lowest standing price we hold, and a link to its full review.

  1. 11
    bmiMDVerified partner

    From $129/mo

    8.2
  2. 12
    HealthRXVerified partner

    From $165/mo

    8.2
  3. 13
    Live VitalVerified partner

    From $130/mo

    8.2
  4. 14
    Sesame CareVerified partner

    From $149/mo

    8.1
  5. 15
    PlexusDxVerified partner

    From $99/mo

    8.0
  6. 16
    Sprout HealthVerified partner

    From $99/mo

    8.0
  7. 17
    Belle HealthVerified partner

    From $199/mo

    7.9
  8. 18
    Luvo HealthVerified partner

    From $179/moRuns a menopause program (seller's page, read Oct 30, 2026)

    7.9
  9. 19
    RxSpan MDVerified partner

    From $249/mo

    7.9
  10. 20
    ShedRxVerified partner

    From $149/mo

    7.9
  11. 21
    AgelessRxVerified partner

    From $99/mo

    7.4
  12. 22
    WellorithmVerified partner

    From $247/mo

    7.4
  13. 23
    FoundVerified partner

    From $199/mo

    7.3
  14. 24
    Ivim HealthVerified partner

    From $140/mo

    7.3
  15. 25
    MEDGmVerified partner

    From $169/mo

    7.3
  16. 26
    OakVerified partner

    From $100/mo

    7.2
  17. 27
    Direct MedsVerified partner

    From $249/mo

    7.1
  18. 28
    DudeMedsVerified partner

    From $175/mo

    6.8
  19. 29
    GoodLife HealthVerified partner

    From —

    6.8
  20. 30
    HumeCare+Verified partner

    From $199/mo

    6.6

589 more sellers we track for this

Ranked below the 30 above on the same rubric. Each links to its full review with current pricing.

← See all Semaglutide Providers

Menopause-specific research

We rank the list above the same way for every reader. What differs for menopause is the clinical context, and these evidence reviews go into it:

Frequently Asked Questions

As far as the evidence goes, yes. GLP-1 drugs are the most effective weight-loss medicines in every population studied, and the one review written about peri- and postmenopausal women calls them a valuable tool. Be clear about the limit of that: the same review notes how little data exists on this group, because the pivotal trials were not designed around menopause.
Many women do. No trial we could find has studied the two together, so there is no evidence to quote in either direction, and a prescriber is reasoning from pharmacology rather than trial data. HRT treats the hormonal symptoms and the GLP-1 the appetite and weight. Put both in front of one prescriber who can see your full history.
Some lean mass goes with any large weight loss. A 2026 pooled analysis put it at 25% to 35% of the weight lost on these drugs, against 26% for intensive lifestyle programs, so the share is no worse than dieting. After menopause it comes out of a smaller reserve. The fracture data so far are reassuring but come from people with type 2 diabetes. Protein and resistance training started at the outset are the standard defense, and they work far better than retrofitting them later.
Sources & methodology — as of November 2026
  1. 1.GLP Watchdog — GLP-1 Pricing Index 2026 (our independent dataset)— GLP Watchdog.
  2. 2.STEP 1 Trial — Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding JPH et al.)— New England Journal of Medicine.PMID: 33567185.
  3. 3.SURMOUNT-5 Trial — Tirzepatide vs. Semaglutide Head-to-Head in Obesity (Aronne LJ et al.)— New England Journal of Medicine.PMID: 40353578.
  4. 4.GLP-1 receptor agonists for weight loss for perimenopausal and postmenopausal women: current evidence (Mikdachi H, Dunsmoor-Su R)— Current Opinion in Obstetrics and Gynecology.PMID: 39970049.
  5. 5.Lean Mass Changes With Incretin Therapy Versus Lifestyle Intervention: A Systematic Review and Meta-Analysis of Randomised Controlled Trials (Eisa N, Barood O)— Diabetes, Obesity and Metabolism.PMID: 41877354.
  6. 6.Effect of GLP-1 receptor agonists on bone mineral density, bone metabolism markers, and fracture risk in type 2 diabetes: a systematic review and meta-analysis (Tan Y et al.)— Acta Diabetologica.PMID: 39985672.
  7. 7.Skeletal effect of semaglutide and tirzepatide in patients with increased risk of fractures (Liu Y et al.)— The Journal of Clinical Endocrinology and Metabolism.PMID: 41655226.